Leading oncology drug developers raise $67 million in funding to target cancer's vulnerability to oncogene overactivation.

A new Cambridge biotech incubated at GV (Google Ventures) has launched with a $67 million Series A funding and a new — ...

Frequencies (y axis) were calculated as percentages of tumor samples (x axis) from a given type that harbored an oncogene mutation (z axis) compared with the total number of samples of that tumor ...

(A) Oncogene mutations were grouped together when they occurred within a given gene (e.g., 'KRAS' for all mutations in 'KRAS') or in the same functional domain of the encoded protein (e.g ...

Next-generation approach targets cancer's surprising vulnerability to oncogene overactivation Delphia is leveraging its activation lethality platform to develop highly differentiated, first-in-class ...

It’s said that ancient Greeks inscribed an aphorism in the forecourt of the Temple of Apollo at Delphi: “Nothing in excess.” Enter Delphia Therapeutics, a start-up harnessing the notion of excess to ...

Delphia Therapeutics launched on Thursday having raised $67 million in a Series A financing, which it will use to advance a pipeline of investigational therapies based on activation lethality. Google ...

The company, BridgeBio Oncology Therapeutics, has one drug in the clinic and hopes to soon advance two other candidates.

Introduction Detection of MTC by Measuring Serum Calcitonin (CT) Detection of MTC by Measuring the RET Proto-oncogene References 1-200 References 201-495 Detection of MTC by Measuring Serum ...

Eli Lilly’s merestinib has seen its Phase Transition Success Rate (PTSR) drop after an investigator-led Phase II trial of the ...

Yum Brands Misses Estimates <li /> CVS Tumbles on Q1 Figures <li /> Securing America's Future: New Investments Aim to Reduce ...

The data presented displayed the exceptional specificity and sensitivity of TCR-T cells co-expressing the PD1-41BB CSP with three different 3S-TCRs that recognize the mKRAS (mutant Kirsten rat sarcoma ...